Limitations, agreements, and source contact

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors · Source last updated 2024-12-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

true

limitations And Caveats

description

Trial terminated on May 23, 2022, due to development program termination.

point Of Contact

email

clinicaltrials@deciphera.com

organization

Deciphera Pharmaceuticals, LLC

phone

785-830-2100

title

Clinical Trials

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice